Orthofix Reports First Patient Implants With Legacy Demineralized Bone Matrix

Orthofix Medical Inc. has released to market the Legacy Demineralized Bone Matrix (DBM), a putty for filling voids or gaps in boney defects or traumatic injuries in the spine, pelvis or extremities. The company also announced the first patient implants with Legacy DBM, a material processed by MTF Biologics.  
 
“Bone healing is a dynamic process where multiple factors play an integral role in deciding which biologic best meets the individual needs of the patient to aid them on their road to recovery,” said Dr. Alan Daniels, chief of Spine Surgery at University Orthopedics Inc. in Providence, R.I., who implanted Legacy DBM in the first patient. “Legacy DBM provides a cost-effective option, without compromising clinical experience or the handling needed in a bone matrix.”

Legacy DBM has a puttylike consistency that features desirable handling and can be used as an extender with autograft or allograft or with bone marrow aspirate. It is created through tailored processing methods that preserve the inherent growth factors natural to  bone.
 
“The Legacy DBM is another example of our continued commitment to expand biologic offerings to meet the needs of surgeons and their patients,” Orthofix President of Global Spine Kevin Kenny said. “In the past year alone, we have introduced five new biologics including the Virtuous Lyograft, a first-of-its kind, shelf-stable, and complete autograft substitute. In addition, we recently announced a partnership with CGBio, a developer of innovative bone grafts, representing the first step in bringing Novosis—the next evolution in bone growth factor technology—to the U.S. and Canadian markets. We understand there are unique surgeon users for a wide range of bone-grafting options, and it is our goal to be a leading provider of these biologic offerings to our customers.” 
 
A complementary addition to the biologics offered by Orthofix through its exclusive partnership with MTF Biologics, Legacy DBM joins the recently introduced Virtuous Lyograft, Trinity Elite, FiberFuse Advanced and FiberFuse Strip allografts, and the AlloQuent structural allograft portfolio. In addition to the MTF Biologic solutions, Orthofix markets and distributes the Opus BA bioactive bone graft, Opus Mg Set bone void filler, Opus One osteoconductive scaffold, and the O-Genesis graft delivery system. This portfolio gives surgeons the ability to select the best option to meet their procedural and patient needs.  
 
Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. Its mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedics products are distributed in more than 60 countries.
 
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients worldwide.